This document is meant to answer some of the most common questions that surround pediatric darunavir/ritonavir 120/20mg (pDRV/r) - a new fixed-dose combination of darunavir (DRV)
with ritonavir for children living with HIV (CLHIV) who are at least 3 years old and weigh at least 10kg. Key questions addressed include benefits, potential side effects, price, and considerations for countries when considering adopting and introducing pDRV/r.
Comments